Evidence map›Paper›PMID 38759699›Full record

ArticleTechnology in cancer research & treatment

Efficacy Analysis of Bortezomib Combined with Lenalidomide in Newly Diagnosed Multiple Myeloma with 1q21 Gain/Amp.

Qiaolin Zhou, Jingjing Wen, Fang Xu, Jing Yue, Ya Zhang, Jing Su, Yiping Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qiaolin ZhouHematology Department, Mianyang Central Hospital, School of Medicine. University of Electronic Science and Technology of China, Mianyang, China.
Jingjing WenHematology Department, Mianyang Central Hospital, School of Medicine. University of Electronic Science and Technology of China, Mianyang, China.
Fang XuHematology Department, Mianyang Central Hospital, School of Medicine. University of Electronic Science and Technology of China, Mianyang, China.ORCID 0000-0002-6731-1116
Jing YueHematology Department, Mianyang Central Hospital, School of Medicine. University of Electronic Science and Technology of China, Mianyang, China.
Ya ZhangHematology Department, Mianyang Central Hospital, School of Medicine. University of Electronic Science and Technology of China, Mianyang, China.
Jing SuHematology Department, Mianyang Central Hospital, School of Medicine. University of Electronic Science and Technology of China, Mianyang, China.
Yiping LiuHematology Department, Mianyang Central Hospital, School of Medicine. University of Electronic Science and Technology of China, Mianyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objective1q21 gain/Amp is one of the most common cytogenetic abnormalities. There are controversies about its effects on prognosis and may be associated with inferior outcomes in patients with newly diagnosed multiple myeloma (NDMM). To explore the optimal induction treatment, we analyzed and compared the efficacy of combinations of bortezomib-lenalidomide-dexamethasone (VRD) and only bortezomib-based triplet regimens without lenalidomide (only bortezomib-based) as induction therapy in patients with NDMM with 1q21 gain/Amp.

methodsSeventy-six NDMM patients with 1q21 gain/Amp who were admitted to our center from 2016 to 2022 were retrospectively analyzed in this study. The progression and efficacy of the patients were observed.

resultsWithin our study group, the overall survival rate stood at 75.0%, and the progression-free survival (PFS) rate reached 40.8% in NDMM patients with 1q21 gain/Amp. The best outcome assessment was that 17.1% achieved complete response (CR) and 44.7% achieved very good partial response (VGPR). Patients in the VRD group had a deeper response (VGPR: 63.6%

conclusionsWhen compared with the sequential administration of bortezomib and lenalidomide or only bortezomib-based protocols, NDMM patients with 1q21 gain/Amp may benefit more from VRD as initial treatments.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBortezomibChromosomes, Human, Pair 1LenalidomideMultiple MyelomaAdultAgedAged, 80 and overChromosome AberrationsDexamethasoneFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBortezomibDexamethasoneLenalidomide1q21 gain/Ampbortezomibefficacyinduction treatmentlenalidomidemultiple myelomanewly diagnosed

Identifiers

PMID38759699
PMCPMC11102689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.